FEBRIVAC 3-PLUS

Not authorised

- Clostridium botulinum, type C, strain Stockholm, toxoid
- Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
- Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
- Mink enteritis virus, strain E-MINK F1, Inactivated
- Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated

Product identification

Medicine name:
FEBRIVAC 3-PLUS

Active substance:
Clostridium botulinum, type C, strain Stockholm, toxoid

Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated

Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated

Mink enteritis virus, strain E-MINK F1, Inactivated

Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated

Target species:
Mink

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Clostridium botulinum, type C, strain Stockholm, toxoid
0.80 80% Protective Dose / 1.00 millilitre(s)

Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
8.00 Organisms / 1.00 millilitre(s)

Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
8.00 Organisms / 1.00 millilitre(s)

Mink enteritis virus, strain E-MINK F1, Inactivated
160.00 haemagglutination inhibiting unit(s) / 1.00 millilitre(s)

Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
8.00 Organisms / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI20CL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Revoked

Authorised in:

Netherlands

Package description:

Available only in Dutch

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
IDT Biologika GmbH

Marketing authorisation date:
25/03/1999

Manufacturing sites for batch release:
IDT Biologika GmbH

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 9102

Date of authorisation status change:
15/03/2019

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet